Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Plos One
|
April 1, 2009
CD28 co-stimulation down regulates Th17 development
Salim Bouguermouh, Geneviève Fortin, Nobuyasu Baba, et al.
The Journal of Allergy and Clinical Immunology
|
March 21, 2015
Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis
Shunya Mashiko, Salim Bouguermouh, Manuel Rubio, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 5, 2008
CD47 expression on T cell is a self-control negative regulator of type 1 immune response
Salim Bouguermouh, Vu Quang Van, Julie Martel, et al.
The Journal of Allergy and Clinical Immunology
|
December 2, 2006
Expression of CD103 identifies human regulatory T-cell subsets
Zoulfia Allakhverdi, David Fitzpatrick, Annie Boisvert, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 4, 2008
Cutting edge: CD47 controls the in vivo proliferation and homeostasis of peripheral CD4+ CD25+ Foxp3+ regulatory T cells that express CD103
Vu Quang Van, Jinane Darwiche, Marianne Raymond, et al.
The EMBO Journal
|
November 10, 2006
Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs
Vu Quang Van, Sylvie Lesage, Salim Bouguermouh, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 5, 2006
Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation
Philippe Grimbert, Salim Bouguermouh, Nobuyasu Baba, et al.
Vaccine
|
November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age
Shane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection
Curtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
The New England Journal of Medicine
|
September 15, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Stephen J Thomas, Edson D Moreira, Nicholas Kitchin, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Plos One
|
April 1, 2009
CD28 co-stimulation down regulates Th17 development
Salim Bouguermouh, Geneviève Fortin, Nobuyasu Baba, et al.
The Journal of Allergy and Clinical Immunology
|
March 21, 2015
Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis
Shunya Mashiko, Salim Bouguermouh, Manuel Rubio, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 5, 2008
CD47 expression on T cell is a self-control negative regulator of type 1 immune response
Salim Bouguermouh, Vu Quang Van, Julie Martel, et al.
The Journal of Allergy and Clinical Immunology
|
December 2, 2006
Expression of CD103 identifies human regulatory T-cell subsets
Zoulfia Allakhverdi, David Fitzpatrick, Annie Boisvert, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 4, 2008
Cutting edge: CD47 controls the in vivo proliferation and homeostasis of peripheral CD4+ CD25+ Foxp3+ regulatory T cells that express CD103
Vu Quang Van, Jinane Darwiche, Marianne Raymond, et al.
The EMBO Journal
|
November 10, 2006
Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs
Vu Quang Van, Sylvie Lesage, Salim Bouguermouh, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 5, 2006
Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation
Philippe Grimbert, Salim Bouguermouh, Nobuyasu Baba, et al.
Vaccine
|
November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age
Shane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection
Curtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
The New England Journal of Medicine
|
September 15, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Stephen J Thomas, Edson D Moreira, Nicholas Kitchin, et al.
Page
of 1